Therapeutics

#Academic #AI / data analytics / healthtech / informatics #Biochemistry #Biologics / Biotechnology #Business #Cellular & Molecular biology #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Gene editing #Gene therapy #High Content Screening #Lead discovery #Molecular medicine #Preclinical #Regulatory #RNA #System biology #Systems biology #Therapeutics

Emerging Drug Discovery Alliance Models

Emerging Drug Discovery Alliance Models By Dr Swati Prasad, Mary Louise Bell & Dr Charles McOsker The current environment for early-stage drug discovery and development is fluid and the probability of success continues to be challenging. Advancing an idea from an academic or… Read More

#Archive

#AI / data analytics / healthtech / informatics #Automation / robotics #Business #Cell / tissue culture #Chemistry #Clinical trials #Drug development #Drug discovery #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Medicinal chemistry #Patent Law #Regulatory #RNA #Target validation #Therapeutics

Blockchain Technology in Drug Discovery: Use-Cases in R&D

By Dr Richard Shute There is no doubt that the interest and hype around blockchain or distributed ledger technology (DLT) builds daily. The explosion of articles and books recently is testament to this. But what is a blockchain and how might DLT impact healthcare, Pharma… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biochemistry #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #High Content Screening #Immunology #Oncology #Orphan drugs #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Therapeutics #Toxicology

Oral Peptide Therapeutics – A Holy Grail or Quixotic Quest?

Oral Peptide Therapeutics – A Holy Grail or Quixotic Quest? By Dr Paul Shields Technologies have been honed to overcome many of the challenges of administering peptide therapeutics orally, but obstacles remain before drug developers can fully realise the vast potential. Proteins and… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell therapy #Cellular & Molecular biology #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene therapy #Immunology #Immunology / Virology & Vaccines #Microfluidics #Precision medicine #Regulatory #RNA #Stem cells #Therapeutics #Toxicology

Nanoparticles & Nanomedicines – Exploring The Past, Present and Future

Nanoparticles & Nanomedicines – Exploring The Past, Present and Future By Professor Yvonne Perrie & Dr Euan Ramsay Nanoparticles, and liposomes in particular, are growing in popularity as drug delivery vehicles for anti-cancer agents and inflammatory disease therapies, as well as forming the basis of a new class… Read More

#Archive

#Academic #Analysis #Animal models #Assay development optimisation & technology #Biochemistry #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #Genetics / genomics #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #PCR #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Novel Drug Targets From Phenotypic Screening

Novel Drug Targets From Phenotypic Screening By Dr Jim Freeth, Dr Elizabeth Kingsley & Jo Soden Identifying functional molecules with the potential to be developed into new therapeutics is often the sole aim of phenotypic drug discovery. However, the approach also provides valuable opportunities to uncover previously… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Biologics / Biotechnology #Business #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Immunology #Lead discovery #Preclinical #Regulatory #RNA #Stem cells #Therapeutics

Tackling Multi-Drug Resistant Bacteria

Tackling Multi-Drug Resistant Bacteria By Dr Ankit Mahadevia Antibiotic resistance never should have become the public health crisis we are seeing today. As a society, we thought the problem of bacterial infections had been solved decades ago when more than 200 powerful antibiotics representing different classes such… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Oncology #Pathology #Precision medicine #Regulatory #Screening #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Raising The Bar On The Biologics Potential

Raising The Bar On The Biologics Potential Dr Michael Mouradian In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a… Read More

#Archive

Researcher in a medical lab
#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Bioengineering #Business #Cell / tissue culture #Cell culture #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Genetics / genomics #Genomics #High Content Screening #Lead discovery #Mass spectrometry / NMR #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Advancing the Drug Discovery Pipeline with Early Stage In Vitro ADME and Toxicity Testing

Advancing the Drug Discovery Pipeline with Early Stage In Vitro ADME and Toxicity Testing By Dr Maureen Bunger With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microfluidics #Molecular medicine #Oncology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

3D Cell Culture – A Rapidly Emerging Technique for Drug Discovery

3D Cell Culture – A Rapidly Emerging Technique for Drug Discovery By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Biochemistry #Biomarkers #Business #Cell therapy #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Precision medicine #Regulatory #RNA #Stem cells #Therapeutics

Monitoring the Balance Between Immune Repression and Stimulation in Cancer Immunotherapy

Monitoring the Balance Between Immune Repression and Stimulation in Cancer Immunotherapy By Dr Peter Schulz-Knappe and Dr Georg Lautscham Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies. Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell therapy #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Lead discovery #Molecular medicine #Preclinical #Regulatory #RNA #System biology #Systems biology #Target validation #Therapeutics #Translational #Translational chemistry

The Discoverome – Creative Destruction of Barriers for Faster to Patient Medicines R&D

The Discoverome – Creative Destruction of Barriers for Faster to Patient Medicines R&D By Chris Molloy Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly… Read More

#Archive

Cancer cells
#Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular assays #Chemistry #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genomics #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Metabolomics #Microbiome #Oncology #Orphan drugs #PCR #Regulatory #RNA #Stem cells #Therapeutics

Immuno-Oncology’s Biomarker Dilemma: How to add value in an uncertain development landscape

Immuno-Oncology’s Biomarker Dilemma: How to add value in an uncertain development landscape By Dr Rachel Laing and Olivier Lesueur Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond… Read More

#Archive

#Academic #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Pathology #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Kinases and Drug Discovery: Protein Kinases as a Validated Drug Target

Kinases and Drug Discovery: Protein Kinases as a Validated Drug Target By Professor Said A. Goueli The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Genetics #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Microfluidics #Molecular medicine #Organic chemistry #Patent Law #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

A Strategic Vision For 21st Century Drug Discovery

A Strategic Vision For 21st Century Drug Discovery By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Computational chemistry #Drug development #Drug discovery #Enabling technologies #Genomics #High Content Screening #High throughput screening #Imaging #Lead discovery #Lead optimisation #Microfluidics #Molecular medicine #Patent Law #PCR #Precision medicine #RNA #Screening #Target validation #Therapeutics #Toxicology

Automated Liquid Handler Vendor vs Third Party Plastic Company

Automated Liquid Handler Vendor vs Third Party Plastic Company by Dr John Comley Competing for the disposable pipette tip business. Users of automated liquid handlers today invariably have a choice – obtain disposable pipette tips from the original instrument vendor or purchase a ‘compatible’ product from a third… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Molecular medicine #Oncology #Organic chemistry #Orphan drugs #Pathology #Pharmacogenomics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine

Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers… Read More

#Archive